JMJD3 inhibition in neuroblastoma has been shown to be favorable to carcinogenesis reduction by modulating the expression of key genes involved in the formation of neuroblastoma and notably by reducing MYCN proto-oncogene expression and overexpressing the p53 and the p53 upregulated modulator of apoptosis (PUMA) factors involved in apoptosis. The gene discussed is MYCN; the disease is neuroblastoma.